HDAC8 and nonpapillary renal cell carcinoma: These findings combined with the previous findings indicate that HDAC8 is an ideal target for improving the response to both antiangiogenic targeted therapy and immune checkpoint therapy (specifically anti‐PD‐L1 therapy) in ccRCC.